Frontiers in endocrinology · 2025
The effect of BRAFV600E mutation on radioiodine therapy in patients with papillary thyroid carcinoma: a meta-analysis and systematic review.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Bin, Cen Xiao-Xia, Zhang Bo-Rui, Zhang Wei
Аннотация
OBJECTIVE: The BRAFV600E mutation is one of the most common genetic alterations in papillary thyroid cancer (PTC) and is widely recognized as a factor of poor prognosis. Radioactive iodine (RAI) therapy is recommended after thyroidectomy for patients with high-risk level PTC or distant metastatic PTC. However, the association between BRAFV600E mutation and RAI refractoriness remains controversial and requires additional investigation. This meta-analysis was conducted to evaluate the impact of BRAFV600E mutation on the curative effect of RAI therapy.
MATERIALS AND METHODS: Electronic searches for relevant studies were performed in the databases of PubMed, EMBASE, and the Science Citation Index databases, with publication date after January 2005. The 131I uptakes status, response to RAI therapy and recurrence of RAI therapy were extracted and compared using meta-analysis.
RESULTS: We included 14 eligible studies incorporating 2890 PTC patients, of which 1966 were patients with BRAFV600E mutation. The pooled analysis indicated that BRAFV600E mutation was strongly associated with the loss of iodine avidity (P = 0.0003) in PTC patients, especially in recurrent individuals (P<0.0001). However, BRAFV600E mutation had no significant association on the clinical response or recurrence rate of RAI therapy (P = 0.27 and P = 0.29, respectively).
CONCLUSION: This meta-analysis confirmed the role of BRAFV600E mutation in deterioration of the ability of RAI uptake but provided insufficient evidence to demonstrate that BRAFV600E mutation might impact the clinical response and recurrence after postsurgical RAI therapy for PTC patients.
MATERIALS AND METHODS: Electronic searches for relevant studies were performed in the databases of PubMed, EMBASE, and the Science Citation Index databases, with publication date after January 2005. The 131I uptakes status, response to RAI therapy and recurrence of RAI therapy were extracted and compared using meta-analysis.
RESULTS: We included 14 eligible studies incorporating 2890 PTC patients, of which 1966 were patients with BRAFV600E mutation. The pooled analysis indicated that BRAFV600E mutation was strongly associated with the loss of iodine avidity (P = 0.0003) in PTC patients, especially in recurrent individuals (P<0.0001). However, BRAFV600E mutation had no significant association on the clinical response or recurrence rate of RAI therapy (P = 0.27 and P = 0.29, respectively).
CONCLUSION: This meta-analysis confirmed the role of BRAFV600E mutation in deterioration of the ability of RAI uptake but provided insufficient evidence to demonstrate that BRAFV600E mutation might impact the clinical response and recurrence after postsurgical RAI therapy for PTC patients.